Do you know when Paxlovid should be used to treat COVID-19? Are you aware of the reasons for the mixed results of its phase 2 and phase 3 clinical trial data versus its real-life studies? Do you know what the most significant concern about Paxlovid is for its future application in treating COVID-19? Reputed as…
9 Things You Need to Know About Paxlovid
A Deep Dive Into Oral Antiviral Pills for COVID (Part 1)
As the world figures out how to coexist with COVID-19, the introduction of oral pills looks promising, in addition to the treatments of monoclonal antibodies and remdesivir. In this multiple series of articles, we will review three oral antivirals against COVID: Paxlovid developed by Pfizer, molnupiravir developed by Merck, and Azvudine developed by Genuine Biotech…
Merck Sees 2022 Sales up Nearly 20 Percent, Mostly on New COVID Pill
Merck & Co said on Wednesday it expects its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new COVID-19 pill, molnupiravir. The drugmaker said sales of the COVID-19 drug were $952 million in the fourth quarter, and it expects another $5 billion to $6 billion in…
Pfizer’s Antiviral COVID-19 Pill Approved by Britain’s Health Regulators
Britain’s drugs regulator approved use authorization for Pfizer’s COVID-19 antiviral pill just about one month after it became the first country to approve a similar oral antiviral treatment produced by Merck & Co.’s. The Medicines and Healthcare Products Regulatory Agency (MHRA) said Pfizer’s pill, named Paxlovid, can be given to people aged 18 and older…
NTD Evening News Full Broadcast (December 23)
Former Minnesota police officer Kim Potter is found guilty of first- and second-degree manslaughter, the FDA authorizes the emergency use of Merck’s antiviral pill, and semiconductor giant Intel apologizes to China following a backlash from Chinese consumers.
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`